Cargando…
Pazopanib as a second line treatment for uterine and ovarian carcinosarcoma: a single institutional study
Autores principales: | Nishikawa, Tadaaki, Hasegawa, Kosei, Yabuno, Akira, Yoshida, Hiroyuki, Yasuda, Masanori, Kozawa, Eito, Fujiwara, Keiichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5165070/ https://www.ncbi.nlm.nih.gov/pubmed/27958685 http://dx.doi.org/10.3802/jgo.2017.28.e25 |
Ejemplares similares
-
Advanced Mucinous Adenocarcinoma Arising from a Mature Cystic Teratoma: A Case Report and Literature Review
por: Miyasaka, Aki, et al.
Publicado: (2016) -
Efficacy of pazopanib in FGFR1-amplified uterine carcinosarcoma: A case report
por: Sawayama, Saki, et al.
Publicado: (2022) -
Pulmonary carcinosarcoma showing an obvious response to pazopanib: a case report
por: Tanimoto, Azusa, et al.
Publicado: (2018) -
Association between effector-type regulatory T cells and immune checkpoint expression on CD8(+) T cells in malignant ascites from epithelial ovarian cancer
por: Sato, Sho, et al.
Publicado: (2022) -
Critical appraisal of bevacizumab in the treatment of ovarian cancer
por: Yoshida, Hiroyuki, et al.
Publicado: (2015)